Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/26/2025

Laboratory Screening for Communicable Diseases

Essential Screening Tests for All Populations

Blood-Borne Pathogens

  • The Centers for Disease Control and Prevention recommends HIV antibody/antigen testing, hepatitis B surface antigen (HBsAg), hepatitis C antibody, syphilis serology (RPR or treponemal-specific test), and for sexually active individuals, testing for gonorrhea and chlamydia 1, 2, 3
  • HIV testing should use enzyme-linked immunoassay (EIA) for both HIV-1/2 antibodies and antigen as the preferred initial test, with repeatedly reactive results confirmed by Western immunoblot 2, 3
  • Hepatitis B screening should include HBsAg, and consider adding hepatitis B core antibody (HBcAb) and hepatitis B surface antibody (anti-HBs) for complete immunity assessment 1, 2
  • Hepatitis C screening should include hepatitis C antibody testing 1, 2
  • Syphilis testing should use reverse screening algorithms with treponemal-specific tests first (EIA/chemiluminescence immunoassay) followed by nontreponemal testing (RPR) to confirm 3, 4

Sexually Transmitted Infections

  • The Centers for Disease Control and Prevention recommends testing all sexually active individuals for gonorrhea and chlamydia, with mandatory screening for women under 25 years and consideration for all men and women aged ≥25 years based on risk factors 3, 5
  • Trichomonas screening should be performed for all women 5
  • High-risk populations (MSM) should include extragenital site testing (rectal, oropharyngeal) for gonorrhea and chlamydia 3, 4

Additional Screening Based on Risk Factors

For HIV-Positive or Immunocompromised Patients

  • Toxoplasma gondii serology is essential for risk stratification 1
  • CMV IgG antibody testing is particularly important for patients at low baseline risk 1
  • Tuberculosis screening should include tuberculin skin test or interferon-gamma release assay 1
  • Hepatitis A total antibody testing can determine the need for vaccination 1

For Pregnant Women

  • The American College of Obstetricians and Gynecologists recommends first trimester or initial prenatal visit screening for HIV, syphilis serology, HBsAg, gonorrhea, and chlamydia (if under 25 or high-risk) 6, 7
  • Third trimester repeat screening should include HIV testing (even if previously tested), syphilis in high-risk populations, and chlamydia for at-risk women 6, 7
  • Group B streptococcus screening using both vaginal and rectal swabs should be performed at 35-37 weeks gestation 3, 4

Screening Frequency Considerations

High-Risk Populations Requiring More Frequent Testing

  • Sexually active HIV-infected persons should undergo annual syphilis screening at minimum, with testing every 3-6 months for those with multiple partners, unprotected intercourse, methamphetamine use, or partners engaging in such activities 5
  • MSM should have more frequent STI screening (every 3-6 months) given higher transmission rates 5
  • Individuals with new STD diagnoses should be rescreened for other STIs as co-infection is common 3, 5

Special Testing Scenarios

Transplant Donor/Recipient Screening

  • Comprehensive screening for both donors and recipients should include HIV 1/2 antibody (with nucleic acid testing for high-risk donors), HBsAg, HBcAb, and anti-HBs, HCV antibody, CMV IgG and EBV IgG antibodies, Toxoplasma IgG (especially for heart transplant), syphilis serology (RPR or equivalent), tuberculin skin testing (recipients), and blood cultures (donors) 2, 5, 6

Genital Lesion Evaluation

  • When genital lesions are present, syphilis serology (mandatory), HSV testing via NAAT (preferred over culture for highest sensitivity and HSV typing), and HIV screening (inflammatory epithelium enhances HIV transmission risk) should be performed 4, 6, 7

Laboratory Test Interpretation Nuances

  • Syphilis biologic false-positive RPR/VDRL results are typically low titer (<1:8) and may be associated with injection drug use history 5
  • HIV window period can be affected by transient increases in HIV viral load due to vaccinations and intercurrent illnesses 1
  • HSV serology limitations include high false-positive rates for point-of-care antibody tests in low-risk populations, and type-specific glycoprotein G-based assays are required to distinguish HSV-1 from HSV-2 4

Partner Management

  • Whenever a communicable disease diagnosis is made, sexual contacts must be evaluated and given presumptive treatment to prevent reinfection, as most treatment "failures" represent reinfection from untreated partners 3, 5, 7

REFERENCES